Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 242-745-6 | CAS number: 19009-56-4
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Endpoint summary
Administrative data
Description of key information
LD50 = >2000 mg/kg bw; OECD 420; Anon, 2017
Key value for chemical safety assessment
Acute toxicity: via oral route
Link to relevant study records
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 06 Feb - 27 Feb 2017
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Remarks:
- Study conducted in accordance with international guidelines and in accordance with GLP. All guideline criteria were met.
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 420 (Acute Oral Toxicity - Fixed Dose Method)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.1 bis (Acute Oral Toxicity - Fixed Dose Procedure)
- GLP compliance:
- yes (incl. QA statement)
- Test type:
- fixed dose procedure
- Limit test:
- yes
- Species:
- rat
- Strain:
- Wistar
- Sex:
- female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Envigo RMS (UK) Limited, Oxon, UK
- Females (if applicable) nulliparous and non-pregnant: Yes and yes
- Age at study initiation: 8-12 weeks
- Weight at study initiation: 159-193g. Body weight variation did not exceed ±20% of the mean body weight at the start of treatment.
- Fasting period before study: Overnight fasting before dosing
- Housing: up to four test animals in suspended solid-floor polypropylene cages furnished with wood flakes
- Diet (e.g. ad libitum): ad libitum except for overnight before dosing and approx 3-4 hours after dosing during which time rats were fasted.
- Water (e.g. ad libitum): ad libitum except for approx 3-4 hours after dosing during which time rats were fasted.
- Acclimation period: at least 5 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 19-25°C
- Humidity (%): 30-70%
- Air changes (per hr): at least 15 changes per hour
- Photoperiod (hrs dark / hrs light): 12 hours continuous light / 12 hours darkness
IN-LIFE DATES: From: 06-Feb-2017 To: 27-Feb-2017 - Route of administration:
- oral: gavage
- Vehicle:
- unchanged (no vehicle)
- Remarks:
- For the purpose of the 300 mg/kg dose level the test item was freshly prepared, as required, as a solution in arachis oil BP, because the test item did not dissolve/suspend in distilled water.
- Details on oral exposure:
- VEHICLE
- Concentration in vehicle: For the purpose of the 300 mg/kg dose level (sighting test): 30 mg/mL
- Amount of vehicle (if gavage): For the purpose of the 300 mg/kg dose level (sighting test): Arachis oil BP was used because the test item did not dissolve/suspend in distilled water.
- Justification for choice of vehicle: Arachis oil BP (for the 300 mg/kg dose level) was used because the test item did not dissolve/suspend in distilled water.
- Lot/batch no. (if required): 461/16
- Purity: 98.9%
MAXIMUM DOSE VOLUME APPLIED: 2000 mg/kg
DOSAGE PREPARATION (if unusual): For the purpose of the 300 mg/kg dose level the test item was freshly prepared, as required, as a solution in arachis oil BP. Arachis oil BP was used because the test item did not dissolve/suspend in distilled water.
CLASS METHOD (if applicable)
- Rationale for the selection of the starting dose: In the absence of data regarding the toxicity of the test item, 300 mg/kg was chosen as the starting dose. In the absence of mortality at a dose level of 300 mg/kg bw, an additional animal was dosed with 2000 mg/kg bw. In the absence of mortality at a dose level of 2000 mg/kg bw, an additional 4 animals were dosed with 2000mg/kg bw. - Doses:
- All animals were dosed once only by gavage, using a metal cannula attached to a graduated syringe. The volume administered to each animal was calculated according to the fasted body weight at the time of dosing. Treatment of animals was sequential. Sufficient time was allowed between each dose group to confirm the survival of the previously dosed animals.
A total of 6 females were treated. A single female was treated with 300mg/kg bw. An additional female was treated with 2000mg/kg bw. In the absence of mortality, a further 4 females were treated with 2000mg/kg bw. - No. of animals per sex per dose:
- 1 female in the first sighting test (300 mg/kg bw)
1 female in second sighting test (2000 mg/kg bw)
4 females in the main test (2000 mg/kg bw) - Control animals:
- no
- Details on study design:
- - Duration of observation period following administration: 14 days
- Frequency of observations and weighing: Clinical observations were made 30 minutes, 1,2 and 4 hours after dosing and then daily for 14 days. Individual body weights were recorded on Day 0 (the day of dosing) and on Days 7 and 14.
- Necropsy of survivors performed: Yes
- Other examinations performed: clinical signs, body weight,organ weights, histopathology, other: Morbidity and mortality checks were made twice daily, early and late during normal working days, and once daily at weekends and public holidays. Clinical observations were performed. (Necropsy: External examination and opening of the abdominal and thoracic cavities. The appearance of any macroscopic abnormalities was recorded). - Statistics:
- Not required.
- Key result
- Sex:
- female
- Dose descriptor:
- LD50
- Effect level:
- > 2 000 mg/kg bw
- Based on:
- test mat.
- Remarks on result:
- not determinable due to absence of adverse toxic effects
- Mortality:
- There was no mortality.
- Clinical signs:
- Hunched posture was noted 1, 2 and 4 hours after dosing. No other signs of systemic toxicity were noted.
- Body weight:
- All animals showed expected gains in body weight.
- Gross pathology:
- No abnormalities were noted at necropsy.
- Interpretation of results:
- GHS criteria not met
- Conclusions:
- The acute oral median lethal dose (LD50) of the test item in the female Wistar strain rat was estimated to be greater than 2000 mg/kg body weight.
- Executive summary:
The acute oral toxicity of the test substance was measured using the fixed dose method (OECD 420 and EU Method B. 1) on the Wistar rat strain. One rat was given a dose of 300mg/kg bw (sighting test), followed by one rat given a dose of 2000mg/kg bw, followed by four further rats given a dose of 2000mg/kg bw. Clinical signs and body weight development were monitored during the study. All animals were subjected to gross necropsy.
Under the condition of this study, the acute oral median lethal dose (LD50) of the test item in the female Wistar strain rat was estimated to be greater than 2000 mg/kg body weight.
Based on these results, the test item does not have to be classified and has no obligatory labelling requirement for acute oral toxicity according to the Globally Harmonized System of Classification and Labelling of Chemicals (GHS) of the United Nations (2015) (including all amendments) and Regulation (EC) No 1272/2008 on classification, labelling and packaging of items and mixtures (including all amendments).
Reference
Table 1 presents the clinical observations of the treated animals. In the initial sighting study (dose of 300mg/kg bw), hunched posture was noted 1, 2 and 4 hours after dosing. No other signs of systemic toxicity were noted. For the initial singular animal treated with a dose level of 2000 mg/kg bw, hunched posture was noted 1, 2 and 4 hours after dosing in the initial treated animal. No other signs of systemic toxicity were noted in this animal. No signs of systemic toxicity were noted in the additional four treated animals during the observation period. No abnormalities were noted in necropsies of all animals. Table 2 demonstrates the weight changes throughout the study in the individual test animals. Table 3 demonstrates the necropsy findings of individual test animals.
Table 1. Individual Clinical Observations and Mortality Data
DOSE LEVEL mg/kg |
ANIMAL NUMBER AND SEX |
EFFECTS NOTED AFTER DOSING |
EFFECTS NOTED DURING PERIOD AFTER DOSING |
EFFECTS NOTED DURING PERIOD AFTER DOSING |
|||||||||||||||
1/2 |
1 |
2 |
4 |
1 |
2 |
3 |
4 |
5 |
6 |
7 |
8 |
9 |
10 |
11 |
12 |
13 |
14 |
||
300 |
1-0 Female |
0 |
H |
H |
H |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
2000 |
2-0 Female |
0 |
H |
H |
H |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
3-0 Female |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
|
3-1 Female |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
|
3-2 Female |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
|
3-3 Female |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 = no signs of systemic toxicity
H = hunched posture
Table 2. Individual body weights and body weight changes
DOSE LEVEL mg/kg |
ANIMAL NUMBER & SEX |
BODY WEIGHT (g) AT DAY |
BODY WEIGHT GAIN (g) DURING WEEK |
|||
0 |
7 |
14 |
1 |
2 |
||
300 |
1-0 Female |
183 |
198 |
219 |
15 |
21 |
2000 |
2-0 Female |
159 |
170 |
191 |
11 |
21 |
3-0 Female |
193 |
214 |
221 |
21 |
7 |
|
3-1 Female |
193 |
212 |
224 |
19 |
12 |
|
3-2 Female |
170 |
190 |
230 |
20 |
40 |
|
3-3 Female |
179 |
191 |
228 |
12 |
37 |
Table 3. Individual necropsy findings
DOSE LEVEL mg/kg |
ANIMAL NUMBER AND SEX |
TIME OF DEATH |
MACROSCOPIC OBSERVATIONS |
300 |
1-0 Female |
Killed day 14 |
No abnormalities detected |
2000 |
2-0 Female |
Killed day 14 |
No abnormalities detected |
3-0 Female |
Killed day 14 |
No abnormalities detected |
|
3-1 Female |
Killed day 14 |
No abnormalities detected |
|
3-2 Female |
Killed day 14 |
No abnormalities detected |
|
3-3 Female |
Killed day 14 |
No abnormalities detected |
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Quality of whole database:
- A single key study was submitted which meets the REACH data requirements.
Acute toxicity: via inhalation route
Link to relevant study records
- Endpoint:
- acute toxicity: inhalation
- Data waiving:
- study scientifically not necessary / other information available
- Justification for data waiving:
- other:
- Justification for type of information:
- JUSTIFICATION FOR DATA WAIVING
In accordance with REACH Annex VIII, Section 8.5.1, Column 2, and ECHA Guidance on Information Requirements and Chemical Safety Assessment, Chapter R.7a, If no systemic effects are observed during acute oral testing, the requirement to conduct inhalation testing should be considered on a case-by-case basis. In the absence of any signs of systemic toxicity in acute and subacute studies conducted for this substance, acute inhalation testing was not considered to be appropriate. No acute hazard via inhalation is concluded for the substance.
Reference
Endpoint conclusion
- Endpoint conclusion:
- no study available
Acute toxicity: via dermal route
Link to relevant study records
- Endpoint:
- acute toxicity: dermal
- Data waiving:
- study scientifically not necessary / other information available
- Justification for data waiving:
- other:
- Justification for type of information:
- The oral LD50 of >2,000 mg/kg bw (not classified) and no signs of toxicity were observed in the in vivo skin sensitisation study, no further justification should be necessary.
Reference
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
In a single key study, the acute oral toxicity of the test substance was measured using the fixed dose method (OECD 420 and EU Method B. 1) on the Wistar rat strain. One rat was given a dose of 300mg/kg bw (sighting test), followed by one rat given a dose of 2000mg/kg bw, followed by four further rats given a dose of 2000mg/kg bw. Clinical signs and body weight development were monitored during the study. All animals were subjected to gross necropsy.
Under the condition of this study, the acute oral median lethal dose (LD50) of the test item in the female Wistar strain rat was estimated to be greater than 2000 mg/kg body weight.
Justification for classification or non-classification
The test item does not meet the classificaiton criteria in accordance with Regulation (EC) No 1272/2008 (CLP).
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
